Merck in agreement with HAPPYneuron to offer first-of-its kind e-Health solution for people living with multiple sclerosis

MerckMerck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in which Merck will receive an exclusive license to the company's cognitive remediation training program for people living with multiple sclerosis (MS). This agreement complements Merck’s broad portfolio of patient support programs in MS and underscores the company's commitment to leveraging digital platforms and technologies to benefit patients in need. Financial terms of the deal were not disclosed.

HAPPYneuron's cognitive remediation program will be available for inclusion in Merck's MSdialog platform, when deemed beneficial for a patient by his/her healthcare provider. HAPPYneuron is designed to improve cognitive skills through brain training by repeated cognitive game training exercises. The in-licensing and integration of HAPPYneuron into the MSdialog platform will allow Merck to expand its first-of-its-kind eHealth solution for people living with MS.

"We have a long-standing commitment to delivering therapeutic and support solutions to people living with MS," said Rehan Verjee, Chief Marketing and Strategy Officer of Merck's biopharma business. "The platform will enhance the attractiveness of MSdialog to patients and HCPs by seeking to address these cognitive deficit symptoms and further fostering the monitoring of the cognitive state of patients."

The HAPPYneuron software-based cognitive training is backed by more than 10 years of clinical data and is designed to address cognitive function across various domains.

HAPPYneuron's suite of cognitive training games are designed to address the cognition challenges that people living with MS face, and the games automatically adjust skill to match the need of the individual - making the platform interesting for the patient and simple for healthcare professionals to use with their patients.

"We are very proud that Merck chose our program," said Franck Tarpin-Bernard, HAPPYneuron President. "This agreement is a strong acknowledgement of the hard work we have achieved these past years to build training programs adapted to the uniqueness of each medical condition. It reinforces our willingness to become a world leader of digital cognitive remediation."

MSdialog is a multi-tenant cloud-based software system for the management of MS that captures and presents patient outcome data to enable better decision-making by patients and providers. The software system provides patients with reminders to take their Rebif® (interferon beta-1a) medication, synchronizes with the new RebiSmart® auto-injector, monitors patient's adherence information to their treatment, and monitors clinical data. MSdialog also allows people with MS to engage in the management of their disease by asking them to complete periodic health report questionnaires based on short forms of published instruments and standard scales, such as the Multiple Sclerosis Quality of Life Inventory (MSQLI) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaires.

MSdialog is currently available in 24 countries. MSdialog with HAPPYneuron will be made available to MS patients initially in a phased roll out beginning in Brazil, Argentina, Israel, Italy, France, and the Netherlands.

About HAPPYneuron
HAPPYneuron is the Smart Health division of SBT Group and a pioneer of brain training industry. Based in France and the United States, HAPPYneuron designs specific cognitive remediation solutions with a rich library of over 200 customizable activities, unique algorithms for analyzing performance, and coaching features.

Its main products target patients suffering from medical conditions that affect cognitive functions (stroke, Alzheimer's, schizophrenia, depression, multiple sclerosis, learning and attention disorders, etc.) and health professionals (speech therapists, neuropsychologists, occupational therapists, psychiatrists , etc.) looking for powerful rehabilitation tools. With its experimented scientific and technological knowledge, HAPPYneuron also adapts and integrates its programs inside third-party platforms (pharmaceutical industry, insurance companies, etc.).

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...